ARTV ARTIVA BIOTHERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ARTIVA BIOTHERAPEUTICS INC reported revenue of n/a, net income of −$25.0M and diluted EPS of −$0.63; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
ARTV annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$89.8M, net income −$83.9M (margin n/a), EPS −$3.43
- Fiscal year ended Dec 2024: revenue $251K, gross profit n/a, operating income −$67.3M, net income −$65.4M (margin -26045.0%), EPS −$5.81
- Fiscal year ended Dec 2023: revenue $33.5M, gross profit n/a, operating income −$30.7M, net income −$28.7M (margin -85.8%), EPS −$35.78
ARTV quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$25.0M, EPS −$0.63
- Quarter ended Mar 31, 2026: revenue n/a, net income −$23.5M, EPS −$0.95
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$20.8M, EPS −$0.85
- Quarter ended Sep 30, 2025: revenue n/a, net income −$21.5M, EPS −$0.88
- Quarter ended Jun 30, 2025: revenue n/a, net income −$21.3M, EPS −$0.87
- Quarter ended Mar 31, 2025: revenue n/a, net income −$20.3M, EPS −$0.83
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$16.1M, EPS $34.35
- Quarter ended Sep 30, 2024: revenue n/a, net income −$17.5M, EPS −$0.92
- Quarter ended Jun 30, 2024: revenue n/a, net income −$17.8M, EPS −$22.00
- Quarter ended Mar 31, 2024: revenue $251K, net income −$14.0M, EPS −$17.24
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$12.0M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $26.7M, net income $11.3M, EPS $1.62
- Quarter ended Jun 30, 2023: revenue $3.50M, net income −$11.3M, EPS −$14.09
- Quarter ended Mar 31, 2023: revenue n/a, net income −$16.7M, EPS n/a
ARTV cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$76.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$55.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$47.4M, share buybacks n/a
ARTV balance sheet
- Jun 30, 2026: cash $301M, total assets $369M, total liabilities $21.1M, shareholders' equity $348M
- Mar 31, 2026: cash $21.0M, total assets $106M, total liabilities $18.1M, shareholders' equity $87.8M
- Dec 31, 2025: cash $26.7M, total assets $131M, total liabilities $21.0M, shareholders' equity $110M
- Sep 30, 2025: cash $25.5M, total assets $149M, total liabilities $19.6M, shareholders' equity $129M
- Jun 30, 2025: cash $28.5M, total assets $169M, total liabilities $20.4M, shareholders' equity $149M
- Mar 31, 2025: cash $30.4M, total assets $191M, total liabilities $22.5M, shareholders' equity $169M
- Dec 31, 2024: cash $40.2M, total assets $210M, total liabilities $22.9M, shareholders' equity $187M
- Sep 30, 2024: cash $55.9M, total assets $226M, total liabilities $24.6M, shareholders' equity $201M
What is ARTV's revenue?
ARTIVA BIOTHERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.
Is ARTV profitable?
No. ARTIVA BIOTHERAPEUTICS INC lost $90.8M over the last four quarters.
What is ARTV's EPS?
Diluted earnings per share over the last four quarters were −$3.31; −$0.63 in the latest quarter.